Skip to main content
S&P 5007,376.86+0.31%DOW51,285.73-0.46%NASDAQ24,579.42+1.09%BTC$75,946.00-0.25%ETH$2,243.57+0.21%GOLD$4,079.50-0.83%OIL$90.34-0.20%
Smart Investors Daily
SID Premium
SN

NYSE · SNY

Sanofi

Healthcare · Drug Manufacturers - General

$47.04

Up+$0.13 (+0.28%)

Updated Nov 8, 2026, 8:34 AM

SID Score

7.7/10

Composite research score

Smart Money

54/100

Neutral

Market cap
119.04B
P/E ratio
11.2
Dividend yield
4.70%
52-week range
$39.07 – $52.68
Volume
3.9M
Avg. volume
2.95M

Price performance · SNY

SNY price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Nov 6, 2026

SNY closed at $47.04 after 20 trading sessions, up 18.37% for the selected period.

Last close
$47.04
Period change
+18.37%
Period low
$39.12
Period high
$47.47
Daily close
View OHLC price history
SNY OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 6, 2026$45.63$47.16$45.58$47.043.9M
Nov 5, 2026$47.48$47.88$46.715$46.917.11M
Nov 4, 2026$46.85$47.49$46.4601$47.475.49M
Nov 3, 2026$45.53$45.70$45.055$45.335.63M
Nov 2, 2026$44.50$45.59$44.50$45.557.37M
Oct 30, 2026$44.82$45.30$44.2325$44.3415.1M
Oct 29, 2026$42.34$43.15$42.17$43.134.27M
Oct 28, 2026$41.83$42.33$41.63$42.242.91M
Oct 27, 2026$41.55$41.965$41.5324$41.892.45M
Oct 26, 2026$41.76$41.89$41.45$41.792.68M
Oct 23, 2026$41.70$41.75$41.33$41.602.01M
Oct 22, 2026$41.17$42.11$41.07$41.963.46M
Oct 21, 2026$41.20$41.54$40.84$40.973.11M
Oct 20, 2026$40.62$41.45$40.56$41.404.24M
Oct 19, 2026$39.84$40.11$39.505$39.573.62M
Oct 16, 2026$40.36$40.61$40.16$40.614.63M
Oct 15, 2026$40.64$40.87$40.17$40.295.05M
Oct 14, 2026$39.37$39.995$39.33$39.775.34M
Oct 13, 2026$40.12$40.12$39.07$39.123.99M
Oct 12, 2026$40.24$40.315$39.685$39.742.94M

Latest SNY news

The latest Smart Investors Daily articles mentioning SNY.

Stock researchCompany · Overview

SNY research

Overview

Company profile and research snapshot.

Company profile

Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$57.02
Implied upside
—
Analysts
14
SNY recent ratings
DateFirmRatingTarget
Sep 23, 2026ROTHSCHILD & CO REDBURNNeutral—
Sep 21, 2026BERENBERGBuy—
Sep 8, 2026LEERINK PARTNERSOutperform—
Sep 4, 2026ODDO BHFBuy—
Aug 31, 2026INTESA SANPAOLO EQUITY RESEARCHBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 7, 2026

Is Early B Cell Cancer Data Altering The Investment Case For Nurix Therapeutics (NRIX)?

Nurix Therapeutics reported that Sanofi terminated the Phase 1 trial and broader SAR448272 STAT6 degrader program, while Nurix remains eligible for milestones and royalties from other partnered assets. Separately, Nurix highlighted new Phase 1a/1b data for bexobrutideg in relapsed or refractory CLL/SLL showing high response rates and continued favorable tolerability. The loss of one STAT6 program reduces potential collaboration inflows. However, fresh bexobrutideg data supports Nurix...

Yahoo · Nov 6, 2026

Novavax Q3 Earnings Call Highlights

Novavax (NASDAQ:NVAX) raised its 2026 revenue framework after partner Sanofi began a late-stage trial of a combination influenza and COVID-19 vaccine in Europe, triggering a $125 million milestone payment for the vaccine technology company. The company also reported a narrower third-quarter net los

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By